Medical Pharmacology Chapter 27: Gastrointestinal Pharmacology Practice Questions

Serotonin 5-HT₃ receptors and irritable bowel syndrome (IBS):
1. Blockade of these receptors decrease visceral afferent sensation such as nausea, pain and bloating.
2. Antagonism of central 5-HT₃ receptors decrease CNS responses to visceral afferent stimulation.
3. 5-HT₃ receptor antagonism influence enteric cholinergic nerve terminals resulting in reduced colonic motility and a lengthening of total colonic transit time.
4. A & B
5. B & C
6. A & C
7. A, B & C
This/these 5-HT₃ blocker(s) has been approved for managing patients with severe irritable bowel syndrome with diarrhea.
1. Ondansetron
2. Alosetron
3. Dolasetron
4. Palonosetron
Alosetron:
1. High incidence of ischemic colitis (0.3%) led to withdrawal from the US market
2. Reapproval of the agent with limited distribution for women with severe diarrhea-predominant IBS by the FDA required prescription, physician certification, consent protocol and significant patient education.
3. Both
4. Neither
Alosetron absorption and metabolism:
1. Rapidly absorbed from the G.I. tract
2. Metabolism by the liver microsomal drug metabolizing system (cytochrome P450 dependent)
3. Both
4. Neither
Most important serious adverse reaction(s) following alosetron administration:
1. Constipation
2. Ischemic colitis
3. Both
4. Neither
Eluxadoline (Viberzi) and receptor interaction.
1. "Mixed" μ (mu) opioid receptor agonist
2. δ (delta) opioid receptor blocker
3. κ (kappa) opioid receptor agonist
4. A & B
5. B & C
6. A & C
7. A, B & C
Eluxadoline (Viberzi) in the IBS setting:
1. Tends to produce constipation patients with IBS
2. Decreases abdominal pain
3. Reduces diarrhea
4. A & B
5. B & C
6. A & C
7. A, B & C
Eluxadoline dose is dependent in part on whether or not the diarrhea-predominant IBS patient has a gallbladder.
1. True
2. False
Eluxadoline should not be administered to this/these patients:
1. Patients with a history of pancreatitis
2. Patients with pancreatic structural disease
3. Both
4. Neither
Eluxadoline should not be administered to this/these categories patients:
1. Patients with known sphincter of body disease/dysfunction.
2. Patients who may have biliary duct obstruction.
3. Both
4. Neither

Medical Pharmacology: Gastrointestinal Pharmacology Practice Questions